Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 15, Number 8—August 2009

Dispatch

Chronic Invasive Aspergillosis caused by Aspergillus viridinutans

Donald C. Vinh1, Yvonne R. Shea1, Pamela A. Jones, Alexandra F. Freeman, Adrian Zelazny, and Steven M. HollandComments to Author 
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (D.C. Vinh, Y.R. Shea, P.A. Jones, A. Zelazny, S.M. Holland); National Cancer Institute-Frederick, Frederick, Maryland, USA (A.F. Freeman)

Main Article

Table

Antifungal drug susceptibility results of Aspergillus viridinutans isolates relative to A. fumigatus reported at 48 hours*

Isolate Amphotericin B MIC, mg/L Itraconazole MIC, mg/L Voriconazole MIC, mg/L Posaconazole MIC, mg/L Caspofungin MEC, mg/L Terbinafine MIC, mg/L
Patient 1 4 1 1 0.06 0.25 ND
Patient 2† 2–8 8 2–4 <0.016–0.5 0.06–0.25 0.125–1
A. fumigatus B-5233‡ 0.5 0.5 0.5 0.125 0.25 2

*MEC, minimal effective concentration; ND, not determined.
†Composite results of 3 isolates from the patient.
‡Clinical isolate from patient with a fatal case of aspergillosis (courtesy of K.J. Kwon-Chung, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA).

Main Article

1These authors contributed equally to this article.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO